Cart
sales@molnova.com
Seratrodast
CAS No. 112665-43-7
Seratrodast( AA2414 | A-73001 | ABT-001 )
Catalog No. M10444 CAS No. 112665-43-7
Seratrodast (INN) is a thromboxane A2 (TXA2) receptor (TP receptor) antagonist used primarily in the treatment of asthma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 39 | In Stock |
|
| 25MG | 59 | In Stock |
|
| 50MG | 77 | In Stock |
|
| 100MG | 128 | In Stock |
|
| 200MG | 165 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSeratrodast
-
NoteResearch use only, not for human use.
-
Brief DescriptionSeratrodast (INN) is a thromboxane A2 (TXA2) receptor (TP receptor) antagonist used primarily in the treatment of asthma.
-
DescriptionSeratrodast (INN) is a thromboxane A2 (TXA2) receptor (TP receptor) antagonist used primarily in the treatment of asthma. It was the first TP receptor antagonist that was developed as an anti-asthmatic drug and received marketing approval in Japan in 1997.
-
In Vitro——
-
In Vivo——
-
SynonymsAA2414 | A-73001 | ABT-001
-
PathwayChromatin/Epigenetic
-
TargetCOX
-
RecptorCOX| TXA2R
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number112665-43-7
-
Formula Weight354.44
-
Molecular FormulaC22H26O4
-
Purity>98% (HPLC)
-
SolubilitySoluble in Water
-
SMILESO=C(O)CCCCCC(C(C1=O)=C(C)C(C(C)=C1C)=O)C2=CC=CC=C2
-
Chemical Name(+-)-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Endo S, Akiyama K. Nihon Rinsho. 1996 Nov;54(11):3045-8.
molnova catalog
related products
-
Pamicogrel
Pamicogrel is an inhibitor of COX. Pamicogrel has platelet anti-aggregatory properties which is under development by Kanebo for chronic arterial occlusion.
-
Sulfasalazine
Sulfasalazine, a sulfa agent and a derivative of mesalazine, is used primarily as an anti-inflammatory agent.
-
Bufexamac
Bufexamac is a COX inhibitor for IFN-α release.
